Compare PDLB & SGHT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PDLB | SGHT |
|---|---|---|
| Founded | 1960 | 2011 |
| Country | United States | United States |
| Employees | 218 | N/A |
| Industry | | Medical Specialities |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 405.9M | 193.2M |
| IPO Year | 2017 | 2021 |
| Metric | PDLB | SGHT |
|---|---|---|
| Price | $17.44 | $8.25 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $6.66 |
| AVG Volume (30 Days) | 69.1K | ★ 186.6K |
| Earning Date | 01-27-2026 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 142.83 | N/A |
| EPS | ★ 0.89 | N/A |
| Revenue | ★ $96,252,000.00 | $76,052,000.00 |
| Revenue This Year | $10.97 | N/A |
| Revenue Next Year | $8.59 | $12.47 |
| P/E Ratio | $18.98 | ★ N/A |
| Revenue Growth | ★ 26.04 | N/A |
| 52 Week Low | $10.88 | $2.03 |
| 52 Week High | $16.99 | $8.80 |
| Indicator | PDLB | SGHT |
|---|---|---|
| Relative Strength Index (RSI) | 74.68 | 61.77 |
| Support Level | $15.65 | $8.04 |
| Resistance Level | $16.09 | $8.63 |
| Average True Range (ATR) | 0.40 | 0.51 |
| MACD | 0.15 | -0.11 |
| Stochastic Oscillator | 83.76 | 62.24 |
Ponce Financial Group Inc, is a United States-based holding company. Its business consists of taking deposits from the general public and investing those deposits, together with funds generated from operations, in mortgage loans, consisting of one-to-four-family residential, multi-family residential, non-residential property and construction and land, and, to a lesser extent, business, and consumer loans. The company also invests in securities, which consists of securities issued by the U.S. Government and federal agencies and mortgage-backed securities issued by the United States government-sponsored enterprises. Some of the products and services include checking solutions, online and mobile banking, merchant credit card services, and others.
Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. Its Surgical Glaucoma segment's product portfolio features the OMNI Surgical System, a device that facilitates the performance of both canaloplasty and trabeculotomy with a single device and single corneal incision to reduce intraocular pressure in adult patients with primary open-angle glaucoma. The company's Dry Eye segment's product portfolio consists of the TearCare System for ophthalmologists and optometrists. It derives key revenue from the Surgical Glaucoma segment.